Added to YB: 2026-03-16
Pitch date: 2026-03-13
GLSI [bullish]
Greenwich LifeSciences, Inc.
Author Info
Banyan Lane Capital aims to present actionable investment research on asymmetric opportunities that, in many cases, are not front and center for investors. Sign up for the newsletter.
Company Info
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania.
Market Cap
$368.1M
Pitch Price
N/A
Price Target
212.30 (+694%)
Dividend
N/A
EV/EBITDA
-18.60
P/E
-18.19
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Greenwich LifeSciences, Inc. - $GLSI
GLSI (overview): Phase IIb: 0% recurrence vs 11% placebo (p=0.03) in HER2+ breast cancer vaccine. Phase III FLAMINGO-01 targeting 500 pts, interim at 14 events (est Q3'26-Q1'27). Open-label Arm 3: ~80% recurrence reduction vs historical. CEO owns 40%, buying at $7-$30; insiders locked thru Sep'26. 25% float shorted (1.6M/6.4M shares). AACR abstracts Mar 17, full data Apr 17. Fast Track granted. Risks: $12.5M cash vs $9.5M burn, single-asset, governance (CEO=CFO), dilution likely
Read full article (17 min)